INTERPHARM HOLDINGS INC

Form 4

February 29, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

OMB APPROVAL

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * TULLIS DICKERSON CAPITAL FOCUS III, L.P.

(Middle)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

[IPA]

INTERPHARM HOLDINGS INC

(Check all applicable)

Director Officer (give title 10% Owner Other (specify

TWO GREENWICH PLAZA, 4TH

(Street)

(State)

(First)

FLOOR

(Last)

(City)

(Instr. 3)

4. If Amendment, Date Original

3. Date of Earliest Transaction

(Month/Day/Year)

02/28/2008

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

(A)

or

(Zip)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

below)

GREENWICH, CT 06830

1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (I) Ownership (Instr. 4) (Instr. 4)

Transaction(s) (Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Transaction Date 3A. Deemed 1. Title of 5. Number of Derivative 6. Date Exercisable and Derivative (Month/Day/Year) Execution Date, if TransactionSecurities Acquired (A) or **Expiration Date** Conversion

1

7. Title

Underly

Edgar Filing: INTERPHARM HOLDINGS INC - Form 4

Security (Instr. 3)	or Exercise Price of		any (Month/Day/Year)	Code (Instr. 8)	Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3
	Derivative Security			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Warrants	\$ 1.639	02/28/2008		J <u>(1)</u>		2,281,914	05/26/2006	05/26/2011	Comn
Series B-1 Convertible Preferred Stock	\$ 1.5338	02/28/2008		J <u>(1)</u>		10,000	05/26/2006	<u>(2)</u>	Comn
New Warrants	\$ 0.95	02/28/2008		J <u>(1)</u>	2,281,914		02/28/2008	02/28/2013	Comn
Series D-1 Convertible Preferred Stock	\$ 0.95	02/28/2008		J <u>(1)</u>	10,413		02/28/2008	<u>(5)</u>	Comn
Convertible Notes	\$ 0.95	02/28/2008		J <u>(6)</u>	877,194		02/28/2008	<u>(7)</u>	Comn
Note Warrants	\$ 0.95	02/28/2008		J <u>(6)</u>	307,017		02/28/2008	02/28/2013	Comn

Reporting Owners

Reporting Owner Name / Address	Relationships					
Topotting O mark A mark / A mark / Mark A ma	Director	10% Owner	Officer	Other		
TULLIS DICKERSON CAPITAL FOCUS III, L.P. TWO GREENWICH PLAZA, 4TH FLOOR GREENWICH, CT 06830		X				
NEUSCHELER JOAN P 2 GREENWICH PLAZA, 4TH FLOOR GREENWICH, CT 06830	X	X				
TULLIS JAMES L L 2 GREENWICH PLAZA, 4TH FLOOR GREENWICH, CT 06830		X				
Dickerson Thomas TWO GREENWICH PLAZA 4TH FLOOR GREENWICH, CT 06830		X				
		X				

Reporting Owners 2

Edgar Filing: INTERPHARM HOLDINGS INC - Form 4

Hohnke Lyle TWO GREENWICH PLAZA 4TH FLOOR GREENWICH, CT 06830

Buono Timothy TWO GREENWICH PLAZA 4TH FLOOR GREENWICH, CT 06830

X

Signatures

Tullis-Dickerson Capital Focus III, L.P., By: Tullis-Dickerson Capital Focus III, L.L.C., Its: General Partner, By: /s/ Joan P. Neuscheler, Principal

02/29/2008

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Pursuant to an agreement among Interpharm Holdings Inc. (the "Issuer"), Capital Focus III and certain other parties, on February 28, 2008, the Issuer (i) exchanged the Series B-1 Preferred Stock held by Capital Focus III, for new shares of the Issuer's Series D-1 Convertible Preferred Stock, par value \$0.01, which Series D-1 Preferred Stock is convertible into the Common Stock pursuant to the

- (1) terms of the Certificate of Designations, Preferences and Rights of Series D-1 Convertible Preferred Stock of the Issuer (the "Series D-1 COD"); and (ii) Capital Focus III exchanged the Warrant previously held by it for a new warrant (the "New Warrants") to purchase 2,281,914 shares of Common Stock at an exercise price of \$0.95 per share. Capital Focus III received 1.04125 shares of Series D-1 Preferred Stock for each exchanged share of their respective Series B-1 Preferred Stock.
- (2) The Series B-1 Convertible Preferred Stock has no expiration date.
 - Tullis-Dickerson Partners III, L.L.C. ("Partners III"), is the sole general partner of Tullis-Dickerson Capital Focus III, L.P. ("Capital Focus III"). Joan P. Neuscheler ("Neuscheler"), James L. L. Tullis ("Tullis"), Thomas P. Dickerson ("Dickerson"), Lyle A. Hohnke ("Hohnke") and Timothy M. Buono ("Buono" and together with Capital Focus III, Partners III, Neuscheler, Tullis, Dickerson and
- (3) Hohnke, the "Reporting Persons") share voting and/or dispositive power over all shares owned by the above entities. The Reporting Persons disclaim beneficial ownership of the shares of Common Stock beneficially owned except to the extent of their pecuniary interests therein and this report shall not be deemed an admission that any of Partners III, Neuscheler, Tullis, Dickerson, Hohnke or Buono is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- (4) Capital Focus III paid \$1,000 for each unit consisting of one share of Series B-1 Convertible Preferred Stock and 228.1914 Warrants.
- (5) The Series D-1 Convertible Preferred Stock has no expiration date.
 - Pursuant to an agreement (the "Note Purchase Agreement") among the Issuer, Capital Focus III and certain other purchasers (together, the "Purchasers"), the Issuer sold to Capital Focus III, \$833,334 in aggregate principal amount of the Issuer's Secured 12% Notes due 2009 (the "Non-Convertible Notes"). Pursuant to the terms of the Note Purchase Agreement, on February 28, 2008 the Issuer exchanged the
- (6) Non-Convertible Notes of Capital Focus III for (i) \$833,334 in aggregate principal amount of the Issuer's Secured Convertible 12% Notes due 2009 (the "Convertible Notes"), which notes are convertible into shares of Common Stock at a conversion price of \$0.95 per share and (ii) warrants (the "Note Warrants") to purchase an aggregate of 307,017 shares of Common Stock at an exercise price of \$0.95 per share.
- October 1, 2009, provided in the event the Issuer's senior credit facility is amended, refinanced or extended such that the maturity date of the senior credit facility is later than February 1, 2011, the maturity of the Convertible Notes shall be extended to October 1, 2010.

Remarks:

Capital Focus III has designated Neuscheler to serve on the Issuer's Board.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3